MegaRobo raises $200M to build AI-driven robotic laboratories
The Chinese company is securing funding to create systems where AI can design, execute, and learn from physical experiments.
The short version
- MegaRobo raised nearly $200M in a round including the Oman Investment Authority and CMB International.
- The company builds systems that link AI models to robots to design and run physical experiments.
- The firm serves over 500 customers, primarily in the biotech, drug manufacturing, and research sectors.
- MegaRobo plans to expand its global footprint into North America, Europe, the Middle East, and Asia.
Why it matters
This move signals a shift from AI simply analyzing existing data to AI actively generating new knowledge through physical interaction. It could significantly accelerate the pace of drug discovery and materials science.
Securing global expansion capital
MegaRobo Technologies, a Chinese company specializing in lab automation, announced it has raised nearly $200M in its latest funding round. This new capital injection comes from a diverse group of investors, including the Oman Investment Authority, which serves as the sovereign wealth fund for Oman. CMB International also joined the round as a new investor.
The funding round also saw continued support from existing backers, such as Asia Investment Capital, Granite Asia, and Sinovation Ventures. While the company did not disclose its specific valuation following this round, the total amount raised to date is approximately $600M. This includes a $300M Series C round that was backed by Goldman Sachs in 2022.
With this new capital, MegaRobo intends to scale its operations on a global level. The company plans to expand its reach across North America, Europe, the Middle East, and Asia. This expansion aims to bring its automated laboratory technology to a wider international market of researchers and industrial partners.
From digital models to physical tests
While current AI models are highly capable of reading scientific papers and predicting molecular structures, they still require physical verification to prove their theories. MegaRobo addresses this gap by linking AI models directly to robotic systems and laboratory tools. This setup allows a model to plan a specific test, execute it using robots, and then analyze the results to determine the next step.
This cycle creates a feedback loop where the AI learns from real-world outcomes rather than just simulated data. By interacting with physical hardware, the system can refine its designs based on actual laboratory results. This process helps bridge the gap between theoretical computer science and practical laboratory science.
Founder and CEO Daniel Huang explained that this shift allows AI to help create new knowledge, materials, processes, and products. By moving beyond interpretation, the system can actively contribute to the creation of new physical entities that do not yet exist in any database.
Serving the biotech and drug sectors
MegaRobo currently serves more than 500 customers, with a heavy concentration in the pharmaceutical and biotechnology industries. These clients include drug makers and various research labs that require high-throughput testing and precise automation. The company's technology is designed to streamline the complex workflows required for modern scientific discovery.
One of the company's primary offerings is the Megalaxy Lab. This platform allows scientists and AI agents to send specific tests to robot labs, and it has already served more than 200 of these clients. By automating the repetitive and precise tasks of a lab, the system enables faster iteration on complex chemical and biological problems.
The company is also involved in collaborative projects like Poreva Open, a protein design contest. This initiative involves partnerships with Tencent Cloud and the DNA maker Twist Bioscience. Through these projects, MegaRobo is helping to establish benchmarks for AI-designed proteins based on actual laboratory results rather than just digital predictions.
A growing landscape of physical AI
The investment in MegaRobo is part of a broader trend of capital flowing into AI-driven drug design and physical automation. For instance, Alphabet’s Isomorphic Labs recently raised $5B, and Chai Discovery secured $400M in July. These figures highlight the massive interest in using machine learning to accelerate the development of new medicines and materials.
Other companies are also building the infrastructure necessary to test AI designs in the physical world. In Berlin, Dunia Innovations is currently constructing a €280M robotic lab specifically for this purpose. These developments suggest a growing infrastructure of 'physical AI' labs designed to validate the outputs of large-scale models.
MegaRobo intends to apply its technology to fields beyond traditional scientific research. The company mentioned it plans to use its automation systems in ways similar to Jeff Bezos’ physical AI lab. This suggests a future where robotic automation and AI-driven experimentation could be applied to various industrial processes and manufacturing techniques.
What to watch
- How quickly MegaRobo can establish physical lab hubs in North America and Europe.
- The success rate of the 10,000 AI-designed proteins being tested in the Megalaxy Lab.
Try it
Look up the Poreva Open protein design contest to see how companies are benchmarking AI-designed proteins.
Sources and links
- ReportingThe Next Web: the article we sourced
First reported by The Next Web. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.